Skip to main content
Premium Trial:

Request an Annual Quote

Survival Extension

In a presentation at the European Society for Medical Oncology, researchers reported that Roche's Perjeta (pertuzumab) could extend patients' lives, the New York Times reports.

According to lead researcher Sandra Swain from the MedStar Washington Hospital Center, patients who received the drug, which treats metastatic breast cancer, had a median survival time 16 months longer than those in the control group.

Perjeta targets the HER2 protein, which is overexpressed in some 20 percent of breast cancers, and it is supposed to be used in conjunction with another Roche drug, Herceptin (trastuzumab), which is directed at a different part of the same protein.

The US Food and Drug Administration approved Perjeta in 2012 through a priority review, as Pharmacogenomics Reporter noted at the time.

The Times says it is now the standard of care in the US, though only about half of eligible women receive the drug. It notes that this study, which the drugmaker funded, could lead to an uptick in use.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.